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Integrating patient preferences and clinical trial data in a 
Bayesian model for quantitative benefit-risk assessment 
Introduction: 
Regulators increasingly incorporate patients’ 
view on benefit-risk tradeoffs but little is known 
on how to integrate elicited preferences into the 
quantitative models. There is little knowledge on 
how to integrate these preferences with clinical 
performance data and how to use knowledge 
about the uncertainty surrounding both types of 
parameters (preference and performance). 
Methods: 
A multi criteria decision analysis (MCDA) model was developed 
that integrates clinical trial data, elicited patient preferences and 
uncertainty surrounding these estimates. Stochastic 
characteristics of preference and drug performance parameters 
can be approximated from stated preference studies and 
performance data from systematic reviews or RCT’s. Risk and 
benefit scores of drugs are then simulated with Monte Carlo 
methods using approximated distributions.  
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Results: 
The model was applied to an anti-depressants case. We included two benefit and one risk criteria (figure 1). 
Preference data was derived from an analytical hierarchy process study with 12 major depression disorder patients 
who were currently in remission and the performance data (pooled odds ratio’s compared to placebo) were derived 
from a systematic review. The distribution around preferences was approximated with a bootstrap method, the 
distribution around performance data was approximated with a normal distribution in the log domain. The simulations 
show all drugs have high (≈1) acceptabilities (figure 2). The problem is more sensitive to performance information 
than to preference information and most sensitive to the adverse events performance criterion.  
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Figure 1: MCDA structure for the 
antidepressants case. 
Conclusion: 
Using this MCDA model it is possible to include patient preference in a quantitative risk-benefit assessment model. 
The model allows integration of stochastic uncertainty concerning preference and performance. It demonstrates that 
comprehensive presentation of data is possible.  
Figure 2: Risk-benefit plane. All simulation runs are 
below the μ=1 threshold and are thus acceptable. 
Figure 3: A value sensitivity graph for the adverse events weight and drug A (left). A decision sensitivity graph 
for drug A (middle). A ranking sensitivity graph for drug B and its performance on the response criterion 
(right). In the ranking sensitivity graph, the green line is drug B’s probability of being rank=1, blue of rank 2 
and red of rank 3. In all graphs, the two black vertical lines denote the 95% CI of the parameter on the x-axis. 
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